Search

everythinglearnresearchcommunity

for

Search:↓

Erlotinib may cause scarring hair loss.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Protein kinase C epsilon may increase skin cancer risk by affecting nearby cells.

GnRH treatment can reduce breast cancer cell invasion.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

EBV infection increases a specific keratin variant in carcinoma cells, possibly affecting cell structure and cancer progression.

A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.

Natural products may help treat Non-Small Cell Lung Cancer by causing cancer cell death through ferroptosis.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

A super thin DIEP flap can effectively reconstruct scalp defects with good skin coverage and contour.

Tislelizumab can cause cutaneous lupus erythematosus.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

New treatments and management strategies for skin conditions like melanoma and Spitz naevi were discussed at the dermatologists' meeting.

A 72-year-old man with sudden taste issues and hair growth was diagnosed with a severe stomach cancer and died within 5 months.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Cetuximab can cause skin cysts after acne-like eruptions.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Androgen receptors play a key role in male development and prostate cancer, with treatments targeting androgen action.

Matriptase is crucial for skin, hair, and immune cell health, and its imbalance can lead to cancer.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

Retinoic acid can either maintain stem cells or make them specialize, depending on the cell type.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.